Growth hormone (GH) is used as a prescription biologic pharmaceutical to treat children's growth disorders and adult growth hormone deficiency. Existing bioassays used in the manufacture and characterisation of growth hormone are expensive, tedious and require the sacrificing of rodents. Researchers at The University of Queensland (UQ) have developed an in vitro receptor-based cell proliferation assay for assessing the potency of human GH. The UQ cell line, designated BaFB2B2, expresses surface human GH receptors and proliferates in a dose dependent manner to human GH. From a manufacturing control perspective, this receptor-based method offers increased sample throughput and improved accuracy and precision compared with both the rat weight gain and tibial growth plate bioassays. The assay is highly specific for human GH and has been adopted by a number of biotech companies producing recombinant human GH.